Alx Oncology Holdings (ALXO) Profit After Tax (2019 - 2026)
Alx Oncology Holdings (ALXO) reported Profit After Tax of -$17.9 million for Q1 2026, up 41.71% on a YoY basis from -$12.7 million in Q1 2025, and up 21.54% sequentially from -$22.8 million in Q4 2025.
Alx Oncology Holdings (ALXO) Profit After Tax (2019 - 2026) Analysis & Trends
Alx Oncology Holdings (ALXO) has 8 years of Profit After Tax data on file, last reported at -$17.9 million in Q1 2026.
- For the quarter ending Q1 2026, Profit After Tax rose 41.71% year-over-year to -$17.9 million; the trailing twelve-month figure through Mar 2026 stood at -$88.9 million (up 31.65% YoY), and the FY2025 full-year result was -$101.7 million, up 24.59% from the prior year.
- Profit After Tax climbed to -$17.9 million in Q1 2026, from -$22.8 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$17.9 million in Q1 2026 to a low of -$51.0 million in Q3 2023.
- A 5-year average of -$31.7 million and a median of -$30.7 million in 2022 frame the typical range for Profit After Tax.
- Across the five-year window, Profit After Tax sank 102.29% in 2022 and jumped 41.71% in 2026, its largest moves.
- Tracing ALXO's Profit After Tax over 5 years: stood at -$30.7 million in 2022, then tumbled by 48.07% to -$45.5 million in 2023, then soared by 35.87% to -$29.2 million in 2024, then rose by 21.65% to -$22.8 million in 2025, then increased by 21.54% to -$17.9 million in 2026.
- Business Quant data shows ALXO's Profit After Tax at -$17.9 million in Q1 2026, -$22.8 million in Q4 2025, and -$22.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Alx Oncology Holdings | 211.24 Mn | 211.24 Mn | - | -17.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.93 Mn |
| Dec 31, 2025 | -22.85 Mn |
| Sep 30, 2025 | -22.14 Mn |
| Jun 30, 2025 | -25.95 Mn |
| Mar 31, 2025 | -30.75 Mn |
| Dec 31, 2024 | -29.16 Mn |
| Sep 30, 2024 | -30.71 Mn |
| Jun 30, 2024 | -39.40 Mn |
| Mar 31, 2024 | -35.58 Mn |
| Dec 31, 2023 | -45.47 Mn |
| Sep 30, 2023 | -50.99 Mn |
| Jun 30, 2023 | -34.16 Mn |
| Mar 31, 2023 | -30.18 Mn |
| Dec 31, 2022 | -30.71 Mn |
| Sep 30, 2022 | -35.32 Mn |
| Jun 30, 2022 | -32.92 Mn |
| Mar 31, 2022 | -24.53 Mn |
| Dec 31, 2021 | -28.44 Mn |
| Sep 30, 2021 | -24.57 Mn |
| Jun 30, 2021 | -16.27 Mn |